Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of AB-1009 in Adult Participants With Late-Onset Pompe Disease (LOPD)

NCT07282847 is registered in ClinicalTrials.gov with AskBio Inc as lead sponsor.

NCT NCT07282847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07282847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of AB-1009 in Adult Participants With Late-Onset Pompe Disease (LOPD)
Lead sponsor
AskBio Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 15, 2026
Completion date
September 30, 2032
Enrollment
12 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lopd, pompe disease (late-onset), pompe disease late-onset